Renal Cell Carcinoma | Clinical

January 07, 2021

Elizabeth Wulff-Burchfield, MD, discusses the role of immune checkpoint inhibitor combination therapy in metastatic renal cell carcinoma.

January 07, 2021

The role of immunotherapy, HIF-2α inhibitors, and CDK4/6 inhibitors appear encouraging for the treatment of patients with kidney cancer following recent research on targeting von Hippel-Lindau disease-associated renal cell carcinoma.

January 06, 2021

Pazopanib, a tyrosine kinase inhibitor, is active and well-tolerated in patients with poor-risk metastatic clear cell renal cell carcinoma with no new safety signal observed, according to results from the phase 4 FLIPPER clinical trial.

January 04, 2021

Treatment with telaglenastat in combination with cabozantinib did not improve progression-free survival in patients with advanced or metastatic renal cell carcinoma when compared with cabozantinib alone, missing the primary end point of the phase 2 CANTANA clinical trial.

December 05, 2020

Treatment with MK-6482, an investigational HIF2α inhibitor, demonstrated durable efficacy as treatment of patients with Von Hippel-Lindau-associated renal cell carcinoma and non-renal lesions, according to phase 2 data presented during the 21st Annual Meeting of the Society of Urologic Oncology.

December 03, 2020

The novel first-in-class small molecule inhibitor of HIF-2α, PT2385 demonstrated the ability to stabilize disease with tolerable safety in patients with von Hippel-Lindau disease-associated clear cell renal cell carcinoma and non-renal tumors, according to results presented in a poster during the 21st Annual Meeting of the Society of Urologic Oncology.

December 02, 2020

Toni Choueiri, MD, discusses nivolumab, ipilimumab, and cabozantinib combinations in ongoing phase 3 trials as treatment for patients with advanced renal cell carcinoma.

November 30, 2020

During a Targeted Oncology Case Based Peer Perspectives event, Marc Matrana, MD, MS, discussed the case of a 62-year-old male patients with renal cell carcinoma.

November 19, 2020

In an interview with Targeted Oncology, Chung-Han (Joe) Lee, MD, PhD, discussed the use of different targeted therapy and immunotherapy strategies for the treatment of patients with metastatic kidney cancer.

November 18, 2020

In an interview with Targeted Oncology, Thomas E. Hutson, DO, PharmD, discussed the difficult-to-treat nccRCC patient population and the promise of lenvatinib plus everolimus, as well as other combination regimens.